We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Improved Marketing Strategies Contribute to IVD Companies' Success

By LabMedica International staff writers
Posted on 28 Jul 2009
The global economic crisis may give the in vitro diagnostics (IVD) industry an opportunity to achieve commercial success. More...
To do so the industry must earn the approval of several different groups: regulators, payer organizations, healthcare providers, and physicians, all of whom ultimately determine the value of a product and how well it will do in the market. For this reason, strategic market-focused product development and effective commercialization are crucial.

Early adopters--laboratories, leading researchers, and physicians also play an influential role in the development and commercialization of new IVD tests. They are critical to the rapid adoption of new products by most potential users, and should be part of the strategy, according to new market research.

There are several hundred new tests and test platforms in development and near market. If all of these devices make it to market, only some will successfully penetrate it. With the average cost of developing a new diagnostic test at least US$100-200 million, companies will need to improve the efficiency of their research and development and commercialization processes.

Marketing mature products involves a keen understanding of the market parameters that companies can control--product design, pricing, distribution options, and sales training and promotions. The countries where companies intend to market their products must also be considered seriously, whether it is North or South America, the United Kingdom, Europe, Japan, China, or Australia. Companies should invest in research that allows them to understand market parameters that are not in their purview to manage. These uncontrollable elements include economic trends that may result in unexpected obstacles and actions taken by competitors.

Kalorama Information's (Rockville, MD, USA) diagnostic expert, Shara Rosen, R.T. M.B.A. reported that evidence-based medicine is becoming more critical for product success as advances in medical technology create increasingly sophisticated and costly new tests. "Companies might be tempted to reduce spending on marketing in a recession,” said Ms. Rosen "But the reality is that to impress increasingly skeptical payers, they may have to spend more.”

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Kalorama Information


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.